-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efatutazone in Myxoid Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efatutazone in Myxoid Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efatutazone in Myxoid Liposarcoma Drug Details: Efatutazone (CS-7017) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD) Drug...
-
Innovation Ranking
Innovation Ranking – Aeterna Zentaris Inc
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin...
-
Product Insights
NewGrowth Hormone Deficiency – Drugs In Development, 2024
Empower your strategies with our Growth Hormone Deficiency – Drugs In Development, 2024 report and make more profitable business decisions. Growth hormone deficiency (GHD) is a rare and treatable condition that occurs when the pituitary gland does not produce enough growth hormone (GH). GH is a hormone that stimulates growth and metabolism in the body. GHD can affect children and adults, but it has different effects depending on the age of onset. Children with GHD have short stature, delayed puberty, low...
-
Product Insights
NewNeuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2024
Empower your strategies with our Neuromyelitis Optica (Devic's Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Neuromyelitis optica (NMO), also known as Devic's syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems. The Neuromyelitis Optica (Devic's Syndrome) drugs in development market research report provide...
-
Product Insights
NewCancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024
Empower your strategies with our Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according...
-
Product Insights
NewHypoparathyroidism – Drugs In Development, 2024
Empower your strategies with our Hypoparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction) and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Macimorelin Acetate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Macimorelin Acetate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macimorelin Acetate in Growth Hormone Deficiency Drug Details: Macimorelin...
-
Company Profile
Aeterna Zentaris Inc – Company Profile
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – macimorelin acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry macimorelin acetate Drug Details Macimorelin acetate (AEZS-130) is under development for the treatment cancer-induced...